d(CH2)5[Tyr(Me)2]AVP   Click here for help

GtoPdb Ligand ID: 2223

Synonyms: CGP-25838 | d(CH2)5Tyr(Me)AVP | d(CH2)5[O-methyl-Tyr2]AVP | Pmp[Tyr(Me)2]AVP | SKF-100273 | SKF100273
Comment: Synthetic analogue of AVP
Click here for help
2D Structure
Click here for help
Click here for structure editor
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1ccc(cc1)CC1NC(=O)CC2(CCCCC2)SSCC(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)Cc1ccccc1)CCC(=O)N)CC(=O)N)C(=O)N1CCCC1C(=O)NC(C(=O)NCC(=O)N)CCCN=C(N)N
Isomeric SMILES COc1ccc(cc1)C[C@H]1NC(=O)CC2(CCCCC2)SSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)Cc1ccccc1)CCC(=O)N)CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)N[C@H](C(=O)NCC(=O)N)CCCN=C(N)N
InChI InChI=1S/C52H74N14O12S2/c1-78-32-16-14-31(15-17-32)25-35-46(73)63-36(24-30-10-4-2-5-11-30)47(74)61-34(18-19-40(53)67)45(72)64-37(26-41(54)68)48(75)65-38(29-79-80-52(27-43(70)60-35)20-6-3-7-21-52)50(77)66-23-9-13-39(66)49(76)62-33(12-8-22-58-51(56)57)44(71)59-28-42(55)69/h2,4-5,10-11,14-17,33-39H,3,6-9,12-13,18-29H2,1H3,(H2,53,67)(H2,54,68)(H2,55,69)(H,59,71)(H,60,70)(H,61,74)(H,62,76)(H,63,73)(H,64,72)(H,65,75)(H4,56,57,58)/t33-,34-,35+,36-,37-,38-,39+/m0/s1
InChI Key QVQOGNOOAMQKCE-OVSZNHMYSA-N
References
1. Clineschmidt BV, Lis EV. (1986)
Pharmacological evaluation of d(CH2)5Tyr(Me)AVP as an antagonist of vasopressin-induced contraction of the isolated rat caudal artery.
Arch Int Pharmacodyn Ther, 284 (1): 72-84. [PMID:2950833]
2. Cotte N, Balestre MN, Aumelas A, Mahé E, Phalipou S, Morin D, Hibert M, Manning M, Durroux T, Barberis C et al.. (2000)
Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding.
Eur J Biochem, 267 (13): 4253-63. [PMID:10866830]
3. Jasper JR, Harrell CM, O'Brien JA, Pettibone DJ. (1995)
Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells.
Life Sci, 57 (24): 2253-61. [PMID:7475979]
4. Phalipou S, Cotte N, Carnazzi E, Seyer R, Mahe E, Jard S, Barberis C, Mouillac B. (1997)
Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist.
J Biol Chem, 272 (42): 26536-44. [PMID:9334232]
5. Saito M, Tahara A, Sugimoto T. (1997)
1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor.
Biochem Pharmacol, 53: 1711-1717. [PMID:9264324]
6. Serradeil-Le Gal C, Raufaste D, Double-Cazanave E, Guillon G, Garcia C, Pascal M, Maffrand JP. (2000)
Binding properties of a selective tritiated vasopressin V2 receptor antagonist, [H]-SR 121463.
Kidney Int, 58 (4): 1613-22. [PMID:11012895]
7. Tahara A, Saito M, Sugimoto T, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W et al.. (1998)
Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
Naunyn Schmiedebergs Arch Pharmacol, 357 (1): 63-9. [PMID:9459574]
8. Tahara A, Saito M, Sugimoto T, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, Yatsu T, Uchida W et al.. (1998)
Pharmacological characterization of the human vasopressin receptor subtypes stably expressed in Chinese hamster ovary cells.
Br J Pharmacol, 125 (7): 1463-70. [PMID:9884074]
9. Thibonnier M, Preston JA, Dulin N, Wilkins PL, Berti-Mattera LN, Mattera R. (1997)
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.
Endocrinology, 138 (10): 4109-22. [PMID:9322919]